SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigKahuna, BooDog, KarinCA, noretreat, TOB, starbuxsux
Search This Board:
Last Post: 5/22/2015 1:23:29 PM - Followers: 581 - Board type: Free - Posts Today: 192

Cellceutix Corporation (CTIX)

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
CIK:  0001355250
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.


The above link is kept updated.

Ongoing Human Trials:
Product Pipeline:

Recent News and Press Releases:

Seeking Alpha focus articles on CTIX:

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

SEC Filings:

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure

Cellceutix IP - Patent Filings:

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: *Special Analyst Alert* and 4 Companies that are Worth a Look 05/13/2015 07:00:00 AM
CTIX News: Quarterly Report (10-q) 05/11/2015 02:03:16 PM
CTIX News: Current Report Filing (8-k) 04/27/2015 07:34:19 AM
CTIX News: Securities Registration (section 12(b)) (8-a12b) 04/27/2015 06:28:28 AM
CTIX News: Cellceutix closes $30M stock purchase agreement 04/01/2015 08:59:20 AM
#103486  Sticky Note CTIX May 21st “Understanding QIDP and Other 21st BooDog 05/21/15 11:36:36 AM
#97761  Sticky Note There was actually quite a bit packed into BigKahuna 04/14/15 02:18:26 PM
#95145  Sticky Note $CTIX Lead drug info, News, SEC filings, FDA KarinCA 03/21/15 12:39:45 PM
#92697  Sticky Note upcoming catalysts slcimmuno 02/26/15 09:18:08 AM
#87958  Sticky Note Cellceutix Reports Spleen Lesion 'Disappears' in Patient With starbuxsux 01/20/15 08:25:55 AM
#74575  Sticky Note Cellceutix Announces Positive Top-Line Data From Phase 2b TOB 10/23/14 11:59:10 AM
#103851   Thanks for clarifying! Nateej2001 05/22/15 01:34:01 PM
#103850   Amen Drano. It's 2-3 years out for 58nout 05/22/15 01:33:54 PM
#103849   Let's lay all this to rest, and focus Drano 05/22/15 01:23:29 PM
#103848   I have held and will continue to hold noretreat 05/22/15 01:23:21 PM
#103847   Leo is on record for a lot longer 58nout 05/22/15 01:15:36 PM
#103846   I agree. IMO today's PR is one of FarmaZutical 05/22/15 01:12:44 PM
#103845   It was in the 2nd one, the "letter Drano 05/22/15 01:11:49 PM
#103844   Thank you...I wasn't aware of that. Ebuilder 05/22/15 01:11:28 PM
#103843   "This may surprise some; but, I think the eventhelosers 05/22/15 01:08:13 PM
#103842   58nout, either you misread my post, or I I Need Help 05/22/15 01:08:03 PM
#103841   I guess not to me, obviously. Nateej2001 05/22/15 01:07:46 PM
#103840   I think Schwab does, and possibly Fidelity. Then Drano 05/22/15 01:05:02 PM
#103839   I've been curious, what broker allows shorting of Ebuilder 05/22/15 12:59:33 PM
#103838   INH now this is spaghetti and meatballs. 58nout 05/22/15 12:54:42 PM
#103837   I couldn't agree more LR. Interesting comments from TheHound 05/22/15 12:54:39 PM
#103836   They didn't give any numbers in the press Drano 05/22/15 12:53:40 PM
#103835   Drano, don't take this personally; but, I think I Need Help 05/22/15 12:48:15 PM
#103834   Has the comp*n* ever disclosed how many additional FarmaZutical 05/22/15 12:45:49 PM
#103833   Nice buys! I know a few that got TheHound 05/22/15 12:44:35 PM
#103832   Good call! Very proactive. I hope it's pancreatic TheHound 05/22/15 12:42:41 PM
#103831   Nice! Thanks for the update Leo! TheHound 05/22/15 12:39:56 PM
#103830   Average daily volume, 222,071; today so far, 328,780. Drano 05/22/15 12:39:43 PM
#103829   Absolutely -- Mr. Ehrlich deserves congratulations, not the Drano 05/22/15 12:18:51 PM
#103828   Yes, reverse splits and uplisting have caused problems Drano 05/22/15 12:17:41 PM
#103827   Reporting Increased Enrollment in Cellceutix's Clinical Trial of morecoffee 05/22/15 12:14:45 PM
#103826   I kind of agree with you, but ... . I Need Help 05/22/15 12:12:15 PM
#103825   It happenned January 20th grizzlyman 05/22/15 12:09:40 PM
#103824   I don't think NoRetreat could have been any clearer! dougwur 05/22/15 12:03:29 PM
#103823   There NEVER was a reason to discuss a Drano 05/22/15 11:51:10 AM
#103822   1$ raise would be great... Steinvid 05/22/15 11:46:14 AM
#103821   Now can everyone quit crying about the stock HawkerLaker 05/22/15 11:36:22 AM
#103820   Once Kevetrin is FDA approved for anything, then georgejjl 05/22/15 11:14:09 AM
#103819   If you don't mind sharing, when you say Nateej2001 05/22/15 11:11:47 AM
#103818   Agreed BioHedge; the intention for phase 2/3 was WellSpring 05/22/15 11:07:52 AM
#103817   Stand alone phase 2/3 for a single solid DaubersUP 05/22/15 11:05:50 AM
#103816   A fast track phase 2/3 for kevetrin is BioHedge 05/22/15 11:01:47 AM
#103815   EXPECT NEWS NEXT WEEK REGARDING KEVETRIN FROM THE georgejjl 05/22/15 10:56:22 AM
#103813   out of the way ribbon clerks, the fat 1hb 05/22/15 10:42:38 AM
#103812   This may surprise some; but, I think the I Need Help 05/22/15 10:37:03 AM
#103811   Cellceutix's Kevetrin could be a single agent miracle georgejjl 05/22/15 10:27:52 AM
#103810   Company to Seek FDA Guidance to Pursue Phase georgejjl 05/22/15 10:25:11 AM
#103808   I figured it out. DoubleJ23 05/22/15 10:23:12 AM
#103807   Many wouldn't believe me, but maybe you will georgejjl 05/22/15 10:20:47 AM
#103806   There's a good chance the 2015 low has NanoEngineer 05/22/15 10:14:13 AM
#103805   it's always "up to Leo" to stop govorchin 05/22/15 10:11:59 AM
#103802   Drano TheMonolith 05/22/15 10:09:44 AM
#103801   A good point, and would be alright with that. TheMonolith 05/22/15 10:06:58 AM
#103800   Someone wake the monkey! F1ash 05/22/15 10:04:53 AM
#103799   thanks again to INH and his email. noretreat 05/22/15 10:01:27 AM
#103797   Lol! TheDane 05/22/15 10:00:49 AM